Centanafadine

Centanafadine
Molecular structure of centanafadine
3D representation of a centanafadine molecule
Clinical data
Pronunciationsen-tan-af-a-deen
Trade namesSimtriyo
Other namesCTN; EB-1020; EB1020; EB-1020-SR; DOV-216,419; DOV-216419; DOV216419
AHFS/Drugs.comSimtriyo
License data
Routes of
administration
Oral
Drug classSerotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI); Stimulant
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Protein binding>99%
MetabolismMonoamine oxidase A (MAO-A)
Elimination half-life5.2 hours
ExcretionUrine: 88%
Feces: 7%
Identifiers
  • (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H15N
Molar mass209.292 g·mol−1
3D model (JSmol)
  • C1[C@H]2[C@@]1(CNC2)C3=CC4=CC=CC=C4C=C3
  • InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
  • Key:HKHCSWPSUSWGLI-CABCVRRESA-N

Centanafadine, sold under the brand name Simtriyo, is a medication used for the treatment of attention deficit hyperactivity disorder (ADHD). It is taken orally.

Common side effects of centanafadine include headache, appetite loss, insomnia, nausea, dry mouth, abdominal pain, and rash, among others. It carries a boxed warning for suicidal ideation and behaviors in children and adolescents aged six years and older, as well as for potential abuse, misuse, and addiction. The drug is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with preference for norepinephrine and then dopamine over serotonin, and has stimulant effects.

Centanafadine was approved for medical use in the United States in July 2026. Its scheduling as a controlled substance was pending as of August 2026.